Cell death induced by TNF or serum starvation is independent of ERbB receptor signaling in MCF-7 breast carcinoma cells

International Journal of Cancer

Volumn 86, Issue 5, 2000, Pages 617-625

  Egeblad, Mikala ^a   Jäättelä, Marja ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETACELLULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; NEU DIFFERENTIATION FACTOR; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL DEATH; CELL DENSITY; CELL PROTECTION; CELL SIZE; CELL STRAIN MCF 7; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STARVATION;

BREAST NEOPLASMS; CELL COUNT; CELL DEATH; CELL SIZE; CULTURE MEDIA, SERUM-FREE; FEMALE; HUMANS; LIGANDS; NEUREGULIN-1; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 0034016975     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000601)86:5<617::AID-IJC3>3.0.CO;2-Z     Document Type: Article

References (40)

1. ALROY, I. and YARDEN, Y., The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett., 410, 83-86 (1997).
2. CARDILLO, M., YANKELEVICH, B., MAZUMDER, A., and LUPU, R., Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast cancer cell type to lysis by lymphokine-activated killer cells. Cancer Immunol. Immunother., 43, 19-25 (1996).
3. CHAN, S.D.H., ANTONIUCCI, D.M., FOK, K.S., ALAJOKI, M.L., HARKINS, R.N., THOMPSON, S.A., and WADA, H.G., Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3. J. Biol. Chem., 270, 22608-22613 (1995).
4. DALY, J.M., JANNOT, C.B., BEERLI, R.R., GRAUS-PORTA, D., MAURER, F.G., and HYNES, N.E., Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res., 57, 3804-3811 (1997).
5. DICKSTEIN, B.M., WOSIKOWSKI, K., and BATES, S.E., Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol. Cell. Endocrinol., 110, 205-211 (1995).
6. DONG, Z., BRENNAN, A., LIU, N., YARDEN, Y., LEFKOWITZ, G., MIRSKY, R., and JESSEN, K.R., Neu differentiation factor is a neuron-glial signal and regulates survival, proliferation, and maturation of rat schwann cell precursors. Neuron, 15, 585-596 (1995).
7. EARP, H.S., DAWSON, T.L., LI, X., and YU, H., Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat., 35, 115-132 (1995).
8. FONG, C.J., SHERWOOD, E.R., MENDELSOHN, J., LEE, C., and KOZLOWSKI, J.M., Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res., 52, 5887-5892 (1992).
9. GUY, P.M., PLATKO, J.V., CANTLEY, L.C., CERIONE, R.A., and CARRAWAY, K.L., Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA, 91, 8132-8136 (1994).
10. HARARI, D., TZAHAR, E., ROMANO, J., SHELLY, M., PIERCE, J.H., ANDREWS, G.C., and YARDEN, Y., Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene, 18, 2681-2689 (1999).
11. HARRIS, L.N., YANG, L., TANG, C. YANG, D., and LUPU, R., Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. Clin. Cancer Res., 4, 1005-1012 (1998).
12. HOFFMANN, M., SCHMIDT, M., and WELS, W., Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha. Cancer Immunol. Immunother., 47, 167-175 (1998).
13. HUDZIAK, R.M., LEWIS, G.D., SHALABY, M.R., EESSALU, T.E., AGGARWAL, B.B., ULLRICH, A., and SHEPARD, H.M., Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA. 85, 5102-5106 (1988).
14. JABBAR, S.A., TWENTYMAN, P.R., and WATSON, J.V., The MTT assay underestimates the growth inhibitory effects of interferons. Br. J. Cancer, 60, 523-528 (1989).
15. 2 in breast carcinoma cells. Oncogene, 10, 2297-2305 (1995).
16. KAUFMANN, A.M., LICHTNER, R.B., SCHIRRMACHER, V., and KHAZAIE, K., Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis. Oncogene, 13, 2349-2358 (1996).
17. LARSEN, S.S., EGEBLAD, M., JÄÄTTELÄ, M., and LYKKESFELDT, A.E., Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accompliced by altered expression of receptors in the ErbB-family. Breast Cancer Res. Treat., 58, 41-56 (1999).
18. LICHTENSTEIN, A., BERENSON, J., GERA, J.F., WALDBURGER, K., MARTINEZ-MAZA, O., and BEREK, J.S., Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. Cancer Res., 50, 7364-7370 (1990).
19. MARSHALL, N.J., GOODWIN, C.J., and HOLT, S.J., A critical assessment of the use of microculture tetrazolium assays to measure cell growth and FUNCTION. Growth Reg., 5, 69-84 (1995).
20. MENDELSOHN, J. and FAN, Z., Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst., 89, 341-343 (1997).
21. MOSMANN, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth., 65, 55-63 (1983).
22. MURPHY, D.S., MCHARDY, P., COUTTS, J., MALLON, E.A., GEORGE, W.D., KAYE, S.B., BROWN, R., and KEITH, W.N., Interphase cytogenetic analysis of erbB2 and topoll alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int. J. Cancer, 64, 18-26 (1995).
23. NORMANNO, N., CIARDELLO, F., BRANDT, R., and SALOMON, D.S., Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res. Treat., 29, 11-27 (1994).
24. PEGRAM, M.D., FINN, R.S., ARZOO, K., BERYT, M., PIETRAS, R.J., and SLAMON, D.J., The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15, 537-547 (1997).
25. PELES, E., BACUS, S.S., KOSKI, R.A., LU, H.S., WEN, D., OGDEN, S.G., LEVY, R.B., and YARDEN, Y., Isolation of the Neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell, 69, 205-216 (1992).
26. PETERSON, C. and LEGERSKI, R., High-frequency transformation of human repair-deficient cell lines by an Ebstein-Barr virus-based cDNA expression vector. Gene, 107, 279-284 (1991).
27. PINKAS-KRAMARSKI, R., SHELLY, M., GUARINO, B.C., WANG, L.M., LYASS, L., ALROY, I., ALAMANDI, M., KUO, A., MOYER, J.D., LAVI, S., EISENSTEIN, M., RATZKIN, B.J., SEGER, R., BACUS, S.S., PIERCE, J.H., ANDREWS, G.C., and YARDEN, Y., ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol. Cell. Biol., 18, 6090-6101 (1998).
28. RAJKUMAR, T. and GULLICK, W.J., The type I growth factor receptors in human breast cancer. Breast Cancer Res. Treat., 29, 3-9 (1994).
29. RIESE, D.J., KIM, E.D., ELENIUS, K., BUCKLEY, S., KLAGSBRUN, M., PLOWMAN, G.D., and STERN, D.F., The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. J. Biol. Chem., 271, 20047-20052 (1996).
30. RIESE, D.J. and STERN, D.F., Specificity within the EGF family/ErbB receptor family signaling network. BioEssays, 20, 41-48 (1998).
31. Ross, J.S. and FLETCHER, J.A., The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells, 16, 413-428 (1998).
32. SALOMON, D.S., BRANDT, R., CIARDIELLO, F., and NORMANNO, N., Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19, 183-232 (1995).
33. SCHROEDER, J.A. and LEE, D.C., Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland. Cell Growth Diff., 9, 451-464 (1998).
34. SHEPARD, H.M. and LEWIS, G.D., Resistance of tumor cells to tumor necrosis factor. J. Clin. Immunol., 8, 333-341 (1988).
35. STEIN, D., WU, J., FUQUA, S.A.W., ROONPRAPUNT, C., YAINIK, V., D'EUSTACHIO, P., MOSKOW, J.J., BUCHBERG, A.M., OSBORNE, C.K., and MARGOLIS, B., The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J., 13, 1331-1340 (1994).
36. SUO, Z., EMILSEN, E., TVEIT, K.M., and NESLAND, J.M., Type I protein tyrosine kinases in benign and malignant breast lesions. Histopathol., 33, 514-521 (1998).
37. TRAVIS, A., PINDER, S.E., ROBERTSON, J.F., BELL, J.A., WENCYK, P., GULLICK, W.J., NICHOLSON, R.I., POLLER, D.N., BLAMEY, R.W., ELSTON, C.W., ELLIS, I.O., C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br. J. Cancer, 74, 229-233 (1996).
38. VAUX, D.L. and STRASSER, A., The molecular biology of apoptosis. Proc. Natl. Acad. Sci. USA, 93, 2239-2244 (1996).
39. 2 in tumor necrosis factor induced apoptosis. Proc. Natl. Acad. Sci., 94, 5073-5077 (1997).
40. YU, D., JING, T., LIU, B., YAO, J., TAN, M., MCDONNELL, T.J., and HUNG, M.C., Overexpression of ErbB2 blocks Taxol-induced apoptosis by up-regulation of p21Cipl, which inhibits p34Cdc2 kinase. Mol. Cell, 2, 581-591 (1998).